{"id":679447,"date":"2019-09-03T12:01:00","date_gmt":"2019-09-03T12:01:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=d591b27367f1076580ab6d814b3f3e58"},"modified":"2019-09-03T12:01:00","modified_gmt":"2019-09-03T12:01:00","slug":"forty-seven-inc-granted-fast-track-designation-for-magrolimab-5f9-for-the-treatment-of-myelodysplastic-syndrome-and-acute-myeloid-leukemia","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/forty-seven-inc-granted-fast-track-designation-for-magrolimab-5f9-for-the-treatment-of-myelodysplastic-syndrome-and-acute-myeloid-leukemia\/","title":{"rendered":"Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia"},"content":{"rendered":"<p><![CDATA[MENLO PARK, Calif., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to magrolimab (formerly known as 5F9) for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Magrolimab is a monoclonal antibody against CD47 that is designed to block the \u201cdon\u2019t eat me\u201d signal used by cancer cells to avoid being ingested by macrophages.]]><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71360],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/679447"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=679447"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/679447\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=679447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=679447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=679447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}